NCT06054789 is a NA clinical trial of 68Ga-PSMA-33 in Prostate Cancer, sponsored by Nanjing First Hospital, Nanjing Medical University.

Who is sponsoring NCT06054789?

NCT06054789 is sponsored by Nanjing First Hospital, Nanjing Medical University.

What drugs are being tested in NCT06054789?

Interventions in NCT06054789: 68Ga-PSMA-33.

What condition does NCT06054789 study?

NCT06054789 studies Prostate Cancer.

Is NCT06054789 still recruiting?

NCT06054789 is currently status unknown. Last updated 26 September 2023.

Last reviewed 2023-09-26 · How we verify

NCT06054789

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer

Status unknown NA Last updated 26 September 2023

What this trial tests

NA trial testing 68Ga-PSMA-33 in Prostate Cancer in 8 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
1 October 2023

1 October 2024

Quick facts

Lead sponsor	Nanjing First Hospital, Nanjing Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	8
Start date	1 October 2022
Primary completion	1 October 2023
Estimated completion	1 October 2024
Sites	1 location across China

Drugs / interventions tested

68Ga-PSMA-33 — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Adults 18 to 99, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the pharmacokinetics, dosimetry, tolerance, tumor detection rate of 68Ga-PSMA-33 in patient with Prostate Cancer (PCa).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Preclinical and First-In-Human Evaluation of <sup>68</sup>Ga-PSMA-33, a Novel PSMA Radiotracer with Low Background Signal.
Wu W, Yao X, Yu F, Wu J, et al · · 2026 · PMID 42222801 · DOI 10.1021/acsomega.6c00861

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06054789 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
Last refreshed: 26 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06054789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing